Abstract OT1-12-07: A phase 2 study of chemotherapy de-escalation using a pathological response-guided strategy in patients with HER2-positive, low-risk early breast cancer: PHERGain-2

Authors: José Manuel Pérez-García, Ángel Guerrero-Zotano, Jacques Medioni, Andreas Schneeweiss, Marco Colleoni, Miguel Sampayo-Cordero, Andrea Malfettone, Javier Cortés, Antonio Llombart-Cussac

Published: 2022-03-08

DOI: 10.1158/1538-7445.sabcs21-ot1-12-07

Source: Full article